Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.33

+1.24 (3.34%)

as of Sep 14, 2026, 7:59:59 pm Market Open.

70 watching

Investor Insights

Sep 14, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical is experiencing a turnaround under its current CEO, with a significant 264% increase since January 2023. The company's growth strategy is yielding positive results, which has recently led to an upgrade in its credit rating by Moody's to investment grade. Factors contributing to this positive outlook include a diverse revenue stream, improving operating margins, strong free cash flow, and an expanding pipeline of innovative products. Despite facing challenges in the generic drug market and criticism about its innovation, expert opinions suggest that Teva remains a strong candidate within the healthcare sector, bolstered by solid cash reserves and expectations for further debt reduction. Analysts project a positive price trajectory for the stock, indicating growth potential over the coming months.

Consensus

Positive

Valuation

Undervalued

Similar

Novartis, NVS

TOP PICK

An Israeli company with most of their operations and sales in North America and Europe. A generic drug producer.

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

DON'T BUY

Prefers others.

BUY

One of the world's largest genetic drug manufactor company. The stock has dropped in the last few weeks. This is a good opportunity to buy stocks.

TOP PICK

Wonderful company. Not overvalued.

BUY ON WEAKNESS

Generic drugs is a great sector. This one is the leader. Accumulate on a gradual basis.

HOLD

Generic drug space is a good place to be. A little high now.

TOP PICK

Generic drugs have done very well. Have increased their margins regularily. Steadily moving up.

BUY

Good growth trend. Good products. May drop in the near term.

TOP PICK

Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Aug 23. Up 1%) Still likes. Likess the generic sector in drugs.

TOP PICK

Stable revenue stream and earnings record. Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Mar 15. Up 19%.) Still likes.

PAST TOP PICK

(Was a top pick on June 21. Up 7.1%) Good long term story.

TOP PICK

Over 50 new drugs waiting approval. Cheap.

Showing 256 to 270 of 277 entries

Most Recent Experts

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)